EP1589980A4 - DIAGNOSTIC AND TREATMENT METHODS FOR INTERSTITIAL PULMONARY DISEASES - Google Patents

DIAGNOSTIC AND TREATMENT METHODS FOR INTERSTITIAL PULMONARY DISEASES

Info

Publication number
EP1589980A4
EP1589980A4 EP03811670A EP03811670A EP1589980A4 EP 1589980 A4 EP1589980 A4 EP 1589980A4 EP 03811670 A EP03811670 A EP 03811670A EP 03811670 A EP03811670 A EP 03811670A EP 1589980 A4 EP1589980 A4 EP 1589980A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
treatment
methods
lung disease
interstitial lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03811670A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1589980A2 (en
Inventor
Jeffrey A Whitsett
Stephan W Glasser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of EP1589980A2 publication Critical patent/EP1589980A2/en
Publication of EP1589980A4 publication Critical patent/EP1589980A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP03811670A 2002-12-09 2003-12-09 DIAGNOSTIC AND TREATMENT METHODS FOR INTERSTITIAL PULMONARY DISEASES Withdrawn EP1589980A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43194902P 2002-12-09 2002-12-09
US431949P 2002-12-09
PCT/US2003/038915 WO2004056310A2 (en) 2002-12-09 2003-12-09 Methods of diagnosis and treatment of interstitial lung disease

Publications (2)

Publication Number Publication Date
EP1589980A2 EP1589980A2 (en) 2005-11-02
EP1589980A4 true EP1589980A4 (en) 2007-04-04

Family

ID=32681947

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03811670A Withdrawn EP1589980A4 (en) 2002-12-09 2003-12-09 DIAGNOSTIC AND TREATMENT METHODS FOR INTERSTITIAL PULMONARY DISEASES

Country Status (7)

Country Link
EP (1) EP1589980A4 (zh)
JP (1) JP2006519588A (zh)
CN (1) CN100401896C (zh)
AU (1) AU2003302740A1 (zh)
BR (1) BR0317132A (zh)
CA (1) CA2507613A1 (zh)
WO (1) WO2004056310A2 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009183176A (ja) * 2008-02-05 2009-08-20 Univ Of Tokyo Ｉｌ−１タイプｉｉレセプター遺伝子の欠損変異体マウス
JP5801206B2 (ja) * 2009-01-30 2015-10-28 アルファベータ・エービーＡｌｐｈａＢｅｔａ ＡＢ アルツハイマー病の治療のための化合物および方法
WO2011162655A1 (en) 2010-06-24 2011-12-29 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
WO2012138284A1 (en) 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds
US20170296595A1 (en) * 2014-09-18 2017-10-19 North Carolina State University Mammalian Lung Spheroids and Lung Spheroid Cells and Uses Thereof
WO2021207514A1 (en) * 2020-04-08 2021-10-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease
CN111972354B (zh) * 2019-05-24 2021-11-30 凯斯艾生物科技（苏州）有限公司 一种具有自身免疫特征的间质性肺炎模型的构建方法
US11895994B2 (en) 2019-10-27 2024-02-13 Shanghai Raas Blood Products Co., Ltd. Humanized knock-in mouse expressing human Protein C
CN111296364B (zh) * 2019-10-27 2022-06-24 上海莱士血液制品股份有限公司 一种基因改造的小鼠动物模型基因改造方法及其应用
CN115772539B (zh) * 2022-11-17 2024-06-21 南京医科大学 一种具有ⅰ型气管发育不全表型的双侧肺脏缺失小鼠模型及其构建方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047623A1 (en) * 1999-02-12 2000-08-17 Chiesi Farmaceutici S.P.A. Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant
WO2000076535A1 (en) * 1999-06-11 2000-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
WO2001080633A2 (en) * 2000-04-26 2001-11-01 Children's Hospital Medical Center Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
US6458759B1 (en) * 1996-04-26 2002-10-01 Ony, Inc. Compositions and methods for isolating lung surfactant hydrophobic proteins SP-B and SP-C
US20030221199A1 (en) * 1998-10-20 2003-11-27 Whitsett Jeffrey A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0644200B1 (en) * 1993-01-13 1998-04-29 Ajinomoto Co., Inc. Cell surface protein from brevibacterium lactofermentum

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458759B1 (en) * 1996-04-26 2002-10-01 Ony, Inc. Compositions and methods for isolating lung surfactant hydrophobic proteins SP-B and SP-C
US20030221199A1 (en) * 1998-10-20 2003-11-27 Whitsett Jeffrey A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
WO2000047623A1 (en) * 1999-02-12 2000-08-17 Chiesi Farmaceutici S.P.A. Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant
WO2000076535A1 (en) * 1999-06-11 2000-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
WO2001080633A2 (en) * 2000-04-26 2001-11-01 Children's Hospital Medical Center Surfactant protein d for the prevention and diagnosis of pulmonary emphysema

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AMIN R S ET AL: "Surfactant protein deficiency in familial interstitial lung disease.", THE JOURNAL OF PEDIATRICS. JUL 2001, vol. 139, no. 1, July 2001 (2001-07-01), pages 85 - 92, XP002394844, ISSN: 0022-3476 *
DAVIS A J ET AL: "Lung function in premature lambs and rabbits treated with a recombinant SP-C surfactant.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE FEB 1998, vol. 157, no. 2, February 1998 (1998-02-01), pages 553 - 559, XP002418346, ISSN: 1073-449X *
GLASSER S W ET AL: "Altered stability of pulmonary surfactant in SP-C-deficient mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 22 MAY 2001, vol. 98, no. 11, 22 May 2001 (2001-05-22), pages 6366 - 6371, XP002394842, ISSN: 0027-8424 *
GLASSER STEPHAN W ET AL: "Pneumonitis and emphysema in sp-C gene targeted mice.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 18 APR 2003, vol. 278, no. 16, 18 April 2003 (2003-04-18), pages 14291 - 14298, XP002394847, ISSN: 0021-9258 *
HAFNER D ET AL: "CYCLOOXYGENASE-INHIBITION ENHANCES THE EFFECTS OF RSP-C SURFACTANT THERAPY IN A RAT LAVAGE MODEL OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)", EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, JENA, DE, vol. 55, no. 1, July 2003 (2003-07-01), pages 59 - 68, XP009024125, ISSN: 0940-2993 *
IKEGAMI MACHIKO ET AL: "Deficiency of SP-B reveals protective role of SP-C during oxygen lung injury.", JOURNAL OF APPLIED PHYSIOLOGY (BETHESDA, MD. : 1985) FEB 2002, vol. 92, no. 2, February 2002 (2002-02-01), pages 519 - 526, XP002394843, ISSN: 8750-7587 *
NOGEE LAWRENCE M ET AL: "Mutations in the surfactant protein C gene associated with interstitial lung disease.", CHEST. MAR 2002, vol. 121, no. 3 Suppl, March 2002 (2002-03-01), pages 20S - 21S, XP009070987, ISSN: 0012-3692 *
SANFORD L P ET AL: "Influence of genetic background on knockout mouse phenotypes.", METHODS IN MOLECULAR BIOLOGY (CLIFTON, N.J.) 2001, vol. 158, 2001, pages 217 - 225, XP009071124, ISSN: 1064-3745 *
THOMAS ALAN Q ET AL: "Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 1 MAY 2002, vol. 165, no. 9, 1 May 2002 (2002-05-01), pages 1322 - 1328, XP002394845, ISSN: 1073-449X *

Also Published As

Publication number Publication date
WO2004056310A2 (en) 2004-07-08
BR0317132A (pt) 2005-10-25
CA2507613A1 (en) 2004-07-08
WO2004056310A3 (en) 2005-09-01
JP2006519588A (ja) 2006-08-31
CN100401896C (zh) 2008-07-16
CN1731932A (zh) 2006-02-08
EP1589980A2 (en) 2005-11-02
AU2003302740A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
AU2002303295B2 (en) Diagnosis and treatment of neural disease and injury using microvoltammetry
EP1551990A4 (en) DIAGNOSIS AND TREATMENT OF CHEMOSTORED TUMORS
EP1571968A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
EP1589933A4 (en) COMPOSITIONS AND METHODS FOR DIETUMOR DIAGNOSIS AND TREATMENT
HUP0401127A3 (en) Treatment and diagnosis of macrophage disease
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
IL162201A0 (en) New methods for diagnosis and treatment of tumours
EP1817050A4 (en) DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER
AU2002323258A1 (en) Diagnosis and treatment of vascular disease
AU2002367535A8 (en) Diagnosis and treatment of vascular disease
EP1572091A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
EP1553912A4 (en) COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
EP1578996A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
EP1575571A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
EP1773882A4 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH SIGLEC-6
AU2003291536A8 (en) Method for the diagnosis and treatment of vascular disease
EP1589980A4 (en) DIAGNOSTIC AND TREATMENT METHODS FOR INTERSTITIAL PULMONARY DISEASES
AU2002326813A1 (en) Diagnosis and treatment of vascular disease
TWI347843B (en) Treatment of bacterial diseases of the respiratory organs
AU2003210266A8 (en) Treatment, diagnosis and imaging of disease
AU2003233681A8 (en) Diagnosis and treatment of human dormancy syndrome
AU2002341880A1 (en) Diagnosis and treatment of vascular disease
EP1599226A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT
AU2002341604A1 (en) Diagnosis and treatment of vascular disease
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050609

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 61/00 20060101AFI20060404BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/00 20060101ALI20060828BHEP

Ipc: A01K 67/00 20060101ALI20060828BHEP

Ipc: G01N 33/00 20060101ALI20060828BHEP

Ipc: A61K 33/00 20060101ALI20060828BHEP

Ipc: A61K 31/00 20060101ALI20060828BHEP

Ipc: A01N 61/00 20060101AFI20060404BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070307

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/17 20060101ALI20070226BHEP

Ipc: C12N 15/00 20060101ALI20070226BHEP

Ipc: A01K 67/00 20060101ALI20070226BHEP

Ipc: G01N 33/00 20060101ALI20070226BHEP

Ipc: A61K 33/00 20060101ALI20070226BHEP

Ipc: A61K 31/00 20060101ALI20070226BHEP

Ipc: A01N 61/00 20060101AFI20060404BHEP

17Q First examination report despatched

Effective date: 20070615

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080701